The stock price of DiaMedica Therapeutics Inc (NASDAQ: DMAC) has surged by 7.00 when compared to previous closing price of 3.57, but the company has seen a -5.21% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-05-22 that MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025. Management will be available for one-on-one meetings with investors to discuss the co.
Is It Worth Investing in DiaMedica Therapeutics Inc (NASDAQ: DMAC) Right Now?
Company’s 36-month beta value is 1.20.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DMAC is 24.15M, and currently, short sellers hold a 4.55% ratio of that floaft. The average trading volume of DMAC on June 20, 2025 was 102.06K shares.
DMAC’s Market Performance
DMAC’s stock has seen a -5.21% decrease for the week, with a -10.54% drop in the past month and a -27.10% fall in the past quarter. The volatility ratio for the week is 5.97%, and the volatility levels for the past 30 days are at 2.83% for DiaMedica Therapeutics Inc The simple moving average for the last 20 days is -4.80% for DMAC stock, with a simple moving average of -19.35% for the last 200 days.
Analysts’ Opinion of DMAC
Many brokerage firms have already submitted their reports for DMAC stocks, with H.C. Wainwright repeating the rating for DMAC by listing it as a “Buy.” The predicted price for DMAC in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on October 07, 2024 of the previous year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see DMAC reach a price target of $8. The rating they have provided for DMAC stocks is “Buy” according to the report published on April 24th, 2024.
Oppenheimer gave a rating of “Outperform” to DMAC, setting the target price at $7 in the report published on June 22nd of the previous year.
DMAC Trading at -3.00% from the 50-Day Moving Average
After a stumble in the market that brought DMAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.98% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DMAC starting from Von Koch Thomas, who purchase 1,200,000 shares at the price of $2.50 back on Jun 28 ’24. After this action, Von Koch Thomas now owns 5,526,435 shares of DiaMedica Therapeutics Inc, valued at $3,000,000 using the latest closing price.
STAHLBERG JAN, the 10% Owner of DiaMedica Therapeutics Inc, purchase 1,200,000 shares at $2.50 during a trade that took place back on Jun 28 ’24, which means that STAHLBERG JAN is holding 5,221,608 shares at $3,000,000 based on the most recent closing price.
Stock Fundamentals for DMAC
The total capital return value is set at -0.85. Equity return is now at value -67.25, with -61.30 for asset returns.
Based on DiaMedica Therapeutics Inc (DMAC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -71.43.
Currently, EBITDA for the company is -24.38 million with net debt to EBITDA at 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.02.
Conclusion
In a nutshell, DiaMedica Therapeutics Inc (DMAC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
